Comparing of Cleveland BioLabs Inc. (CBLI) and Aptinyx Inc. (NASDAQ:APTX)

Cleveland BioLabs Inc. (NASDAQ:CBLI) and Aptinyx Inc. (NASDAQ:APTX) are two firms in the Biotechnology that compete against each other. Below is a comparison of their institutional ownership, profitability, risk, dividends, analyst recommendations, earnings and valuation.

Valuation and Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Cleveland BioLabs Inc. 1.77M 9.24 4.35M -0.39 0.00
Aptinyx Inc. 6.72M 27.42 46.41M -1.42 0.00

Demonstrates Cleveland BioLabs Inc. and Aptinyx Inc. earnings per share, gross revenue and valuation.


Table 2 demonstrates the net margins, return on equity and return on assets of Cleveland BioLabs Inc. and Aptinyx Inc.

Net Margins Return on Equity Return on Assets
Cleveland BioLabs Inc. -245.76% -734.3% -56.6%
Aptinyx Inc. -690.63% 0% 0%


The Current Ratio and a Quick Ratio of Cleveland BioLabs Inc. are 3.5 and 3.5. Competitively, Aptinyx Inc. has 21.8 and 21.8 for Current and Quick Ratio. Aptinyx Inc.’s better ability to pay short and long-term obligations than Cleveland BioLabs Inc.

Institutional & Insider Ownership

Roughly 6% of Cleveland BioLabs Inc. shares are owned by institutional investors while 76% of Aptinyx Inc. are owned by institutional investors. Insiders owned 58.15% of Cleveland BioLabs Inc. shares. Competitively, 3.9% are Aptinyx Inc.’s share owned by insiders.


Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Cleveland BioLabs Inc. -4.28% 1.7% -1.65% -33.95% -28.69% -55.36%
Aptinyx Inc. -6.03% -19.01% -34.47% 0% 0% 3.32%

For the past year Cleveland BioLabs Inc. had bearish trend while Aptinyx Inc. had bullish trend.


Aptinyx Inc. beats Cleveland BioLabs Inc. on 6 of the 10 factors.

Cleveland BioLabs, Inc., a biopharmaceutical company, develops novel approaches to activate the immune system and address various medical needs in the United States and the Russian Federation. The companyÂ’s advanced product candidate is entolimod, a Toll-like receptor 5 (TLR5) agonist that is used to prevent death from acute radiation syndrome, and as an oncology drug. It is also developing CBLB612, a pharmacologically optimized synthetic molecule that structurally mimics naturally occurring lipopeptides of Mycoplasma, and activates NF-kB pro-survival and immunoregulatory signaling pathways; and Mobilan, a recombinant non-replicating adenovirus that directs expression of TLR5 and its agonistic ligand. In addition, the company develops CBL0137, a small molecule with a multi-targeted mechanism of action used for the treatment of various types of cancer. Cleveland BioLabs, Inc. has strategic partnerships with The Cleveland Clinic and Roswell Park Cancer Institute. The company was founded in 2003 and is headquartered in Buffalo, New York.

Aptinyx Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel, proprietary, and synthetic small molecules for the treatment of brain and nervous system disorders. It is developing NYX-2925 that is in Phase II clinical trial for the treatment of painful diabetic peripheral neuropathy, as well as in Phase II exploratory clinical trial for fibromyalgia; and NYX-783, an NMDAr receptor that is in Phase I clinical trial for the treatment of post-traumatic stress disorder. The company has a collaboration agreement with Allergan plc. Aptinyx Inc. was founded in 2015 and is headquartered in Evanston, Illinois.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.